#Denmark #Lundbeck #Valby #Vyepti #Rexulti

Lundbeck Reports Impressive Revenue Growth

Lundbeck has delivered noteworthy financial results for the first nine months of 2025, showcasing a remarkable 14% growth in total revenue at constant exchange rates (CER). This growth is especially highlighted by the impressive performance of its strategic brands, Vyepti and Rexulti, which have driven significant sales increases following increased investments and strategic initiatives.

In total, Lundbeck's revenue surged to DKK 18,537 million, reflecting a 13% increase in Danish Krone (DKK). This impressive performance was primarily fueled by strong growth in key markets such as the United States and Europe, where the company has concentrated its sales efforts.

Strategic Brand Performance

Notably, Lundbeck's strategic brands alone contributed substantially to this growth, climbing 20% in revenue and accounting for 77% of the total revenue, with combined sales reaching DKK 14,260 million. In particular, Rexulti and Vyepti emerged as standout performers.

• - Rexulti recorded a revenue of DKK 4,695 million, marking a 26% increase from the previous year. The brand's growth in the U.S. was bolstered by strong demand in segments related to major depressive disorder (MDD) and agitation associated with dementia due to Alzheimer's disease (AADAD).
• - Vyepti, on the other hand, enjoyed an exceptional 57% growth, with revenue hitting DKK 3,254 million. As the fastest-growing anti-CGRP treatment in the U.S., Vyepti's success can be attributed to increasing patient starts and improved persistency.

Lundbeck’s discipline in capital management has allowed the company to continuously reinvest in these high-performing brands, supporting further innovation and expansion. The company's ability to adapt and optimize capital deployment has proven pivotal as it navigates through a complex healthcare market.

Geographic Performance

Lundbeck’s financial highlights were driven by robust performances across different geographical segments:

• - United States: Revenue reached DKK 9,955 million, translating to a staggering 22% growth at CER. This market remains a critical component of Lundbeck’s overall strategy, accounting for nearly 54% of its total revenue.
• - Europe: Achieving DKK 4,318 million, Europe contributed significantly to Lundbeck’s financial outcomes, with a 13% growth compared to its previous year. The consistent demand for products like Rexulti and Brintellix in this region indicates strong market acceptance and brand loyalty.
• - International Operations: Although revenue remained stable at DKK 3,880 million, this segment faced challenges, including localized generic competition affecting growth. It signifies a need for strategic repositioning and innovations in this area to boost future performance.

Financial Guidance and Strategic Developments

In light of these results, Lundbeck has opted to revise its full-year guidance upwards, anticipating revenue growth of 13-14% at CER, up from its previous forecast of 11%-13%. The outlook for adjusted EBITDA growth has also been enhanced to a range of 22-25%, driven largely by the strong performance of Vyepti and Rexulti.

Additionally, significant strategic collaborations have emerged during this quarter, including partnerships aimed at optimizing Lundbeck's research and development capabilities. Collaborations with firms like OpenAI and Contera Pharma promise to enhance Lundbeck’s innovation trajectory, aiming to address pressing medical needs in neurological care.

Conclusion

Overall, Lundbeck’s performance in the first nine months of 2025 highlights its strong market position, driven by pivotal brand performances and strategic operational improvements. The company remains focused on maximizing value through innovation and capital reallocation, with an eye towards further advancements in brain health. Lundbeck is now poised to continue its growth trajectory with a solid strategy in place for the future of neuroscience.